Phase 2 Results of Selinexor in Advanced De- Differentiated (DDLS) Liposarcoma (SEAL) Study: A Phase 2/3, Randomized, Double Blind, Placebo Controlled Cross-Over Study

Phase 2 Results of Selinexor in Advanced De- Differentiated (DDLS) Liposarcoma (SEAL) Study: A Phase 2/3, Randomized, Double Blind, Placebo Controlled Cross-Over Study

Learn More